Alector to Participate in Upcoming Healthcare Conferences
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in two upcoming investor conferences in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in two upcoming investor conferences in New York. The H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 12, 2022, featuring an on-demand corporate presentation at 7:00 a.m. ET. Subsequently, Alector will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference later that day at 5:25 p.m. ET. Webcasts of these events will be accessible on Alector's website for 90 days.
Details
News Market Reaction – ALEC
The recorded move for ALEC in the trading session of this news was +8.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
- H.C. Wainwright 24th Annual Global Investment Conference (New York, New York)
- Monday, September 12, 2022 at 7:00 a.m. ET, on-demand corporate presentation
- Morgan Stanley 20th Annual Global Healthcare Conference (New York, New York)
- Monday, September 12, 2022 at 5:25 p.m. ET, fireside chat
Webcasts will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Alector Contacts:
Martin Forrest
VP, Investor Relations & Corporate Affaris
415-231-5668
martin.forrest@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Eric Kasper/Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.